Implementation Could Be Tough For Rebate Executive Order

On July 24, the Trump administration released three executive orders, which call for regulations allowing drugs to be imported from other countries, requiring Federally Qualified Health Centers to make insulin and epinephrine available to low-income people at the discounted prices set by the 340B Drug Pricing Program, and removing safe harbor protections under the Anti-Kickback statue for prescription drug rebates in Medicare Part D. A fourth executive order would tie drug prices to their list prices in countries with Most Favored Nation status, but it has not yet been released.

Industry experts and trade groups have been particularly critical of the executive order that directs HHS to resurrect the so-called rebate rule, which the administration withdrew in 2019.

© 2025 MMIT
Peter Johnson

Peter Johnson

Peter has worked as a journalist since 2011 and has covered health care since 2020. At AIS Health, Peter covers trends in finance, business and policy that affect the health insurance and pharma sectors. For Health Plan Weekly, he covers all aspects of the U.S. health insurance sector, including employer-sponsored insurance, Medicaid managed care, Medicare Advantage and the Affordable Care Act individual marketplaces. In Radar on Drug Benefits, Peter covers the operations of (and conflicts between) pharmacy benefit managers and pharmaceutical manufacturers, with a particular focus on pricing dynamics and market access. Before joining AIS Health, Peter covered transportation, public safety and local government for various outlets in Seattle, his hometown and current place of residence. He graduated with a B.A. from Colby College.

Related Posts

September 26

News Briefs: Sanders Touts PBM Promise in Pushing for Wegovy, Ozempic Price Cut

READ MORE
republican-and-democratic-party
September 26

Would Red or Blue Election Wins Be Better for PBMs? It’s a Tossup

READ MORE
pharmacist
September 26

Satisfaction With PBM Industry Dips to Record Low in 2024

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today